Limits...
Brimonidine in the treatment of glaucoma and ocular hypertension.

Cantor LB - Ther Clin Risk Manag (2006)

Bottom Line: Brimonidine is safe and well tolerated.Brimonidine-Purite 0.1% is as effective in reducing IOP as the original brimonidine 0.2% solution preserved with benzalkonium chloride.Recent results from preclinical and clinical studies suggest that brimonidine may protect retinal ganglion cells and their projections from damage and death independently of its effects on IOP.

View Article: PubMed Central - PubMed

Affiliation: Department of Ophthalmology, Indiana University Indianapolis, IN, USA.

ABSTRACT
Treatment in glaucoma aims to lower intraocular pressure (IOP) to reduce the risk of progression and vision loss. The alpha2-adrenergic receptor agonist brimonidine effectively lowers IOP and is useful as monotherapy, adjunctive therapy, and replacement therapy in open-angle glaucoma and ocular hypertension. A fixed combination of brimonidine and timolol, available in some countries, reduces IOP as effectively as concomitant therapy with brimonidine and timolol and offers the convenience of 2 drugs in a single eyedrop. Brimonidine is safe and well tolerated. Its most common side-effects are conjunctival hyperemia, allergic conjunctivitis, and ocular pruritus. The newest formulation of brimonidine, brimonidine-Purite 0.1%, has a higher pH to improve the ocular bioavailability of brimonidine. This formulation contains the lowest effective concentration of brimonidine and is preserved with Purite(R) to enhance ocular tolerability. Brimonidine-Purite 0.1% is as effective in reducing IOP as the original brimonidine 0.2% solution preserved with benzalkonium chloride. Recent results from preclinical and clinical studies suggest that brimonidine may protect retinal ganglion cells and their projections from damage and death independently of its effects on IOP. The potential for neuroprotection with brimonidine is an added benefit of its use in glaucoma and ocular hypertension.

No MeSH data available.


Related in: MedlinePlus

Mean change from baseline IOP. Both brimonidine-Purite 0.1% and brimonidine 0.2% provided significant IOP reductions that were sustained throughout 1 year of therapy. The mean IOP reduction was equivalent with the 2 formulations throughout follow-up.Abbreviations: IOP, intraocular pressure.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC1936355&req=5

fig2: Mean change from baseline IOP. Both brimonidine-Purite 0.1% and brimonidine 0.2% provided significant IOP reductions that were sustained throughout 1 year of therapy. The mean IOP reduction was equivalent with the 2 formulations throughout follow-up.Abbreviations: IOP, intraocular pressure.

Mentions: Baseline demographic and ophthalmic characteristics of patients were similar between the 2 treatment groups. Mean IOP at baseline was also comparable between the 2 treatment groups at each hour. Throughout follow-up, mean IOP in each treatment group ranged from 17 to 22 mmHg and was significantly lower than at baseline (p<0.001). The absolute values of the limits of the 95% confidence interval (CI) of the between-group difference in mean IOP were <1.0 mmHg at 12 of 17 timepoints and <1.5 mmHg at all 17 timepoints, demonstrating equivalent efficacy of the study formulations (Figure 1). Analysis of mean change from baseline IOP also showed equivalent efficacy of the study formulations, with the absolute values of the limits of the 95% CI of the between-group difference <1.0 mmHg at 9 of 17 timepoints and consistently <1.5 mmHg. The only significant differences in mean IOP reduction between treatment groups were at 4 PM at months 3 and 12, when the mean IOP reduction was significantly greater with brimonidine-Purite 0.1% than with brimonidine 0.2% (p≤0.043). Brimonidine-Purite 0.1% provided sustained IOP lowering over 12 months of treatment and was as effective as brimonidine 0.2% in reducing IOP at all timepoints. Figure 2 shows the mean change from baseline IOP with each formulation at the 10 AM timepoint of peak effect.


Brimonidine in the treatment of glaucoma and ocular hypertension.

Cantor LB - Ther Clin Risk Manag (2006)

Mean change from baseline IOP. Both brimonidine-Purite 0.1% and brimonidine 0.2% provided significant IOP reductions that were sustained throughout 1 year of therapy. The mean IOP reduction was equivalent with the 2 formulations throughout follow-up.Abbreviations: IOP, intraocular pressure.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC1936355&req=5

fig2: Mean change from baseline IOP. Both brimonidine-Purite 0.1% and brimonidine 0.2% provided significant IOP reductions that were sustained throughout 1 year of therapy. The mean IOP reduction was equivalent with the 2 formulations throughout follow-up.Abbreviations: IOP, intraocular pressure.
Mentions: Baseline demographic and ophthalmic characteristics of patients were similar between the 2 treatment groups. Mean IOP at baseline was also comparable between the 2 treatment groups at each hour. Throughout follow-up, mean IOP in each treatment group ranged from 17 to 22 mmHg and was significantly lower than at baseline (p<0.001). The absolute values of the limits of the 95% confidence interval (CI) of the between-group difference in mean IOP were <1.0 mmHg at 12 of 17 timepoints and <1.5 mmHg at all 17 timepoints, demonstrating equivalent efficacy of the study formulations (Figure 1). Analysis of mean change from baseline IOP also showed equivalent efficacy of the study formulations, with the absolute values of the limits of the 95% CI of the between-group difference <1.0 mmHg at 9 of 17 timepoints and consistently <1.5 mmHg. The only significant differences in mean IOP reduction between treatment groups were at 4 PM at months 3 and 12, when the mean IOP reduction was significantly greater with brimonidine-Purite 0.1% than with brimonidine 0.2% (p≤0.043). Brimonidine-Purite 0.1% provided sustained IOP lowering over 12 months of treatment and was as effective as brimonidine 0.2% in reducing IOP at all timepoints. Figure 2 shows the mean change from baseline IOP with each formulation at the 10 AM timepoint of peak effect.

Bottom Line: Brimonidine is safe and well tolerated.Brimonidine-Purite 0.1% is as effective in reducing IOP as the original brimonidine 0.2% solution preserved with benzalkonium chloride.Recent results from preclinical and clinical studies suggest that brimonidine may protect retinal ganglion cells and their projections from damage and death independently of its effects on IOP.

View Article: PubMed Central - PubMed

Affiliation: Department of Ophthalmology, Indiana University Indianapolis, IN, USA.

ABSTRACT
Treatment in glaucoma aims to lower intraocular pressure (IOP) to reduce the risk of progression and vision loss. The alpha2-adrenergic receptor agonist brimonidine effectively lowers IOP and is useful as monotherapy, adjunctive therapy, and replacement therapy in open-angle glaucoma and ocular hypertension. A fixed combination of brimonidine and timolol, available in some countries, reduces IOP as effectively as concomitant therapy with brimonidine and timolol and offers the convenience of 2 drugs in a single eyedrop. Brimonidine is safe and well tolerated. Its most common side-effects are conjunctival hyperemia, allergic conjunctivitis, and ocular pruritus. The newest formulation of brimonidine, brimonidine-Purite 0.1%, has a higher pH to improve the ocular bioavailability of brimonidine. This formulation contains the lowest effective concentration of brimonidine and is preserved with Purite(R) to enhance ocular tolerability. Brimonidine-Purite 0.1% is as effective in reducing IOP as the original brimonidine 0.2% solution preserved with benzalkonium chloride. Recent results from preclinical and clinical studies suggest that brimonidine may protect retinal ganglion cells and their projections from damage and death independently of its effects on IOP. The potential for neuroprotection with brimonidine is an added benefit of its use in glaucoma and ocular hypertension.

No MeSH data available.


Related in: MedlinePlus